Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma

Mohamad B. Sonbol, Matthew J. Maurer, Mary J. Stenson, Cristine Allmer, Betsy R. Laplant, George J. Weiner, William R. Macon, James R Cerhan, Thomas Elmer Witzig, Mamta Gupta

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Mantle cell lymphoma (MCL) is a unique type of lymphoma with a prognosis intermediate between indolent and aggressive types. The purpose of this study was to study blood cytokine levels in newly diagnosed and relapsed MCL patients with respect to patterns of abnormalities and relationship to the MCL International Prognostic Index (MIPI) score. We analyzed blood levels of 30 cytokines using a multiplex ELISA in 88 patients with newly diagnosed MCL (pre-treatment levels) and 20 with relapsed MCL and compared them with controls without known lymphoma. Elevated cytokine levels were compared with clinical outcome and the MIPI score. In the 88 newly diagnosed MCL patients, we found significantly elevated levels compared with controls of IL-12, IP-10, sIL-2Rα, MIG, IL-1RA, IL-8, MIP-1α, and MIP-1β (all P<0.05). Of these elevated cytokines, sIL-2Rα, IL-8, MIG, MIP-1α, and MIP-1β were predictive of inferior event-free survival, and sIL-2Rα (HR=1.94; P=0.038), IL-8 (HR=2.17; P=0.015), and MIP-1β (HR=2.10; P=0.016) were independent of MIPI score; only sIL-2Rα (HR=2.35; P=0.041) was associated with overall survival after adjustment for MIPI. In the relapsed MCL patient group, the only significantly elevated plasma cytokines that predicted EFS were sIL-2Rα (HR=2.90; P=0.04) and IL-8 (HR=3.75; P=0.02). Elevated blood levels of sIL-2Rα and the pro-inflammatory cytokines IL-8 and MIP-1β are poor prognostic factors in MCL patients and independent of MIPI score. These factors, if validated, will provide important additions to the MIPI and guide the development of new therapies for patients with elevated levels of these cytokines.

Original languageEnglish (US)
Pages (from-to)E223-E227
JournalAmerican Journal of Hematology
Volume89
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Mantle-Cell Lymphoma
Interleukin-8
Cytokines
Lymphoma
Interleukin-12
Disease-Free Survival
Enzyme-Linked Immunosorbent Assay
Survival
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma. / Sonbol, Mohamad B.; Maurer, Matthew J.; Stenson, Mary J.; Allmer, Cristine; Laplant, Betsy R.; Weiner, George J.; Macon, William R.; Cerhan, James R; Witzig, Thomas Elmer; Gupta, Mamta.

In: American Journal of Hematology, Vol. 89, No. 12, 01.12.2014, p. E223-E227.

Research output: Contribution to journalArticle

Sonbol, Mohamad B. ; Maurer, Matthew J. ; Stenson, Mary J. ; Allmer, Cristine ; Laplant, Betsy R. ; Weiner, George J. ; Macon, William R. ; Cerhan, James R ; Witzig, Thomas Elmer ; Gupta, Mamta. / Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma. In: American Journal of Hematology. 2014 ; Vol. 89, No. 12. pp. E223-E227.
@article{3ea3de9a83f84940915620bd18ba52dc,
title = "Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma",
abstract = "Mantle cell lymphoma (MCL) is a unique type of lymphoma with a prognosis intermediate between indolent and aggressive types. The purpose of this study was to study blood cytokine levels in newly diagnosed and relapsed MCL patients with respect to patterns of abnormalities and relationship to the MCL International Prognostic Index (MIPI) score. We analyzed blood levels of 30 cytokines using a multiplex ELISA in 88 patients with newly diagnosed MCL (pre-treatment levels) and 20 with relapsed MCL and compared them with controls without known lymphoma. Elevated cytokine levels were compared with clinical outcome and the MIPI score. In the 88 newly diagnosed MCL patients, we found significantly elevated levels compared with controls of IL-12, IP-10, sIL-2Rα, MIG, IL-1RA, IL-8, MIP-1α, and MIP-1β (all P<0.05). Of these elevated cytokines, sIL-2Rα, IL-8, MIG, MIP-1α, and MIP-1β were predictive of inferior event-free survival, and sIL-2Rα (HR=1.94; P=0.038), IL-8 (HR=2.17; P=0.015), and MIP-1β (HR=2.10; P=0.016) were independent of MIPI score; only sIL-2Rα (HR=2.35; P=0.041) was associated with overall survival after adjustment for MIPI. In the relapsed MCL patient group, the only significantly elevated plasma cytokines that predicted EFS were sIL-2Rα (HR=2.90; P=0.04) and IL-8 (HR=3.75; P=0.02). Elevated blood levels of sIL-2Rα and the pro-inflammatory cytokines IL-8 and MIP-1β are poor prognostic factors in MCL patients and independent of MIPI score. These factors, if validated, will provide important additions to the MIPI and guide the development of new therapies for patients with elevated levels of these cytokines.",
author = "Sonbol, {Mohamad B.} and Maurer, {Matthew J.} and Stenson, {Mary J.} and Cristine Allmer and Laplant, {Betsy R.} and Weiner, {George J.} and Macon, {William R.} and Cerhan, {James R} and Witzig, {Thomas Elmer} and Mamta Gupta",
year = "2014",
month = "12",
day = "1",
doi = "10.1002/ajh.23838",
language = "English (US)",
volume = "89",
pages = "E223--E227",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma

AU - Sonbol, Mohamad B.

AU - Maurer, Matthew J.

AU - Stenson, Mary J.

AU - Allmer, Cristine

AU - Laplant, Betsy R.

AU - Weiner, George J.

AU - Macon, William R.

AU - Cerhan, James R

AU - Witzig, Thomas Elmer

AU - Gupta, Mamta

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Mantle cell lymphoma (MCL) is a unique type of lymphoma with a prognosis intermediate between indolent and aggressive types. The purpose of this study was to study blood cytokine levels in newly diagnosed and relapsed MCL patients with respect to patterns of abnormalities and relationship to the MCL International Prognostic Index (MIPI) score. We analyzed blood levels of 30 cytokines using a multiplex ELISA in 88 patients with newly diagnosed MCL (pre-treatment levels) and 20 with relapsed MCL and compared them with controls without known lymphoma. Elevated cytokine levels were compared with clinical outcome and the MIPI score. In the 88 newly diagnosed MCL patients, we found significantly elevated levels compared with controls of IL-12, IP-10, sIL-2Rα, MIG, IL-1RA, IL-8, MIP-1α, and MIP-1β (all P<0.05). Of these elevated cytokines, sIL-2Rα, IL-8, MIG, MIP-1α, and MIP-1β were predictive of inferior event-free survival, and sIL-2Rα (HR=1.94; P=0.038), IL-8 (HR=2.17; P=0.015), and MIP-1β (HR=2.10; P=0.016) were independent of MIPI score; only sIL-2Rα (HR=2.35; P=0.041) was associated with overall survival after adjustment for MIPI. In the relapsed MCL patient group, the only significantly elevated plasma cytokines that predicted EFS were sIL-2Rα (HR=2.90; P=0.04) and IL-8 (HR=3.75; P=0.02). Elevated blood levels of sIL-2Rα and the pro-inflammatory cytokines IL-8 and MIP-1β are poor prognostic factors in MCL patients and independent of MIPI score. These factors, if validated, will provide important additions to the MIPI and guide the development of new therapies for patients with elevated levels of these cytokines.

AB - Mantle cell lymphoma (MCL) is a unique type of lymphoma with a prognosis intermediate between indolent and aggressive types. The purpose of this study was to study blood cytokine levels in newly diagnosed and relapsed MCL patients with respect to patterns of abnormalities and relationship to the MCL International Prognostic Index (MIPI) score. We analyzed blood levels of 30 cytokines using a multiplex ELISA in 88 patients with newly diagnosed MCL (pre-treatment levels) and 20 with relapsed MCL and compared them with controls without known lymphoma. Elevated cytokine levels were compared with clinical outcome and the MIPI score. In the 88 newly diagnosed MCL patients, we found significantly elevated levels compared with controls of IL-12, IP-10, sIL-2Rα, MIG, IL-1RA, IL-8, MIP-1α, and MIP-1β (all P<0.05). Of these elevated cytokines, sIL-2Rα, IL-8, MIG, MIP-1α, and MIP-1β were predictive of inferior event-free survival, and sIL-2Rα (HR=1.94; P=0.038), IL-8 (HR=2.17; P=0.015), and MIP-1β (HR=2.10; P=0.016) were independent of MIPI score; only sIL-2Rα (HR=2.35; P=0.041) was associated with overall survival after adjustment for MIPI. In the relapsed MCL patient group, the only significantly elevated plasma cytokines that predicted EFS were sIL-2Rα (HR=2.90; P=0.04) and IL-8 (HR=3.75; P=0.02). Elevated blood levels of sIL-2Rα and the pro-inflammatory cytokines IL-8 and MIP-1β are poor prognostic factors in MCL patients and independent of MIPI score. These factors, if validated, will provide important additions to the MIPI and guide the development of new therapies for patients with elevated levels of these cytokines.

UR - http://www.scopus.com/inward/record.url?scp=84937780376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937780376&partnerID=8YFLogxK

U2 - 10.1002/ajh.23838

DO - 10.1002/ajh.23838

M3 - Article

C2 - 25164110

AN - SCOPUS:84937780376

VL - 89

SP - E223-E227

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 12

ER -